ЛЮ Вейнинг (US),ФАН Ксуепинг (US),САЛАНТ Дэвид Джей (US)
申请号：
RU2014132108
公开号：
RU2014132108A
申请日:
2013.01.04
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A pharmaceutical composition comprising a ROBO2 inhibitor that inhibits the biological activity of ROBO2, characterized in that the ROBO2 inhibitor is selected from the group consisting of an anti-ROBO2 antibody or antigen binding fragment thereof that specifically binds to ROBO2, an antisense molecule directed to a nucleic acid encoding ROBO2, a short interfering RNA (siPHK) directed to a nucleic acid encoding ROBO2, an aptamer of RNA or DNA that binds to ROBO2, a structural analogue of ROBO2, a soluble ROBO2 protein and ROBO2 inhibitory Nogo polypeptide, and a pharmaceutically acceptable nositelya.2. The pharmaceutical composition of claim 1, wherein the ROBO2 inhibitor inhibits or reduces the binding of the ROBO2 polypeptide to SLIT2, to Nck, or both. The pharmaceutical composition according to any one of paragraphs. 1 or 2, characterized in that the ROBO2 inhibitor is a structural analogue. 4. The pharmaceutical composition according to any one of paragraphs. 1 or 2, characterized in that the ROBO2 inhibitor is a dominant negative ROBO2.5 polypeptide. The pharmaceutical composition according to any one of paragraphs. 1 or 2, characterized in that the ROBO2 inhibitor is a dominantly negative ROBO2.6 fusion polypeptide. The pharmaceutical composition according to any one of paragraphs. 1 or 2, characterized in that the soluble inhibitor of the ROBO2 protein contains: (i) a fusion polypeptide containing at least one Ig SLIT binding domain selected from the group consisting of: amino acid residues 46-145 in the sequence of SEQ ID NO: 1, amino acid residues 151-237 in the sequence of SEQ ID NO: 1, amino acid residues 30-129 in the sequence of SEQ ID NO: 3 or amino acid residues 135-221 in the sequence of SEQ ID NO: 3； or (ii) a fusion polypeptide containing amino acid residues 881-1378 followed by1. Фармацевтическая композиция, содержащая ингибитор ROBO2, который ингибирует биологическую активность ROBO2, характеризующаяся тем, что ингибитор ROBO2 выбран из группы
